Expert opinion on investigational drugs

Keyphrases

Publications

volume 33, number 5, 2024

Ivana Chim, Ragini Ghiya, Rodney D Sinclair, Samantha Eisman
Novel investigational drugs for alopecia areata and future perspectives. Expert opinion on investigational drugs 33 (5) (2024)
Claudiu T Supuran
Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection. Expert opinion on investigational drugs 33 (5) (2024)
Sophie E Field, Annabel J Curle, Roger A Barker
Inflammation and Huntington's disease - a neglected therapeutic target? Expert opinion on investigational drugs 33 (5) (2024)
Abhishek Gairola, Aaron Wetten, Jessica Dyson
Sodium/bile acid co-transporter inhibitors currently in preclinical or early clinical development for the treatment of primary biliary cholangitis. Expert opinion on investigational drugs 33 (5) (2024)
Giulio Evangelisti, Simone Ferrero, Umberto Perrone, Claudio Gustavino, Eugenio Volpi, Alberto Izzotti, Fabio Barra
Experimental and new investigational drugs for the treatment of uterine fibroids. Expert opinion on investigational drugs 33 (5) (2024)
Claudiu T Supuran
Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection. Expert opinion on investigational drugs 33 (5) (2024)
Sophie E Field, Annabel J Curle, Roger A Barker
Inflammation and Huntington's disease - a neglected therapeutic target? Expert opinion on investigational drugs 33 (5) (2024)
Irene Capelli, Sarah Lerario, Francesca Ciurli, Gian Marco Berti, Valeria Aiello, Michele Provenzano, Gaetano La Manna
Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights. Expert opinion on investigational drugs 33 (5) (2024)

volume 33, number 6, 2024

Francesca R Buccellato, Marianna D'Anca, Gianluca Martino Tartaglia, Massimo Del Fabbro, Daniela Galimberti
Frontotemporal dementia: from genetics to therapeutic approaches. Expert opinion on investigational drugs 33 (6) (2024)
Swetha Byravan, Harini Samarasinghe, Jack Shi Jie Yuan, Syed Haider Tahir, Arumugam Moorthy, Hasan Tahir
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis? Expert opinion on investigational drugs 33 (6) (2024)
Fernanda Karoline Vieira da Silva Torchelsen, Ana Lia Mazzeti, Vanessa Carla Furtado Mosqueira
Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status. Expert opinion on investigational drugs 33 (6) (2024)
Nadia Saoudi González, Paola Valeria Marchese, Iosune Baraibar, Javier Ros, Francesc Salvà, Marta Rodríguez, Clara Salvà, Caterina Vaghi, Adriana Alcaraz, Ariadna García, Josep Tabernero, Elena Élez
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy. Expert opinion on investigational drugs 33 (6) (2024)
Samantha Gibson, Pamela Ellsworth
Emerging therapies for overactive bladder: preclinical, phase I and phase II studies. Expert opinion on investigational drugs 33 (6) (2024)
Prithvi Reddy Akepati, Eric M Gochanour
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis. Expert opinion on investigational drugs 33 (6) (2024)
Swetha Byravan, Harini Samarasinghe, Jack Shi Jie Yuan, Syed Haider Tahir, Arumugam Moorthy, Hasan Tahir
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis? Expert opinion on investigational drugs 33 (6) (2024)
Jiaming Gao, Jingwen Cheng, Wanyu Xie, Ping Zhang, Xuebin Liu, Zaiqi Wang, Baoyuan Zhang
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study. Expert opinion on investigational drugs 33 (6) (2024)
Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, Efstratios Vakirlis, Stamatios Gregoriou
Interleukin antagonists for atopic dermatitis: a new era of therapy. Expert opinion on investigational drugs 33 (6) (2024)
Samantha Gibson, Pamela Ellsworth
Emerging therapies for overactive bladder: preclinical, phase I and phase II studies. Expert opinion on investigational drugs 33 (6) (2024)
Francesca R Buccellato, Marianna D'Anca, Gianluca Martino Tartaglia, Massimo Del Fabbro, Daniela Galimberti
Frontotemporal dementia: from genetics to therapeutic approaches. Expert opinion on investigational drugs 33 (6) (2024)
Saam Foroshani, Avrohom Karp, Wilbert S Aronow, Gregg M Lanier
The role of phosphodiesterase 9A inhibitors in heart failure. Expert opinion on investigational drugs 33 (6) (2024)
Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, Efstratios Vakirlis, Stamatios Gregoriou
Interleukin antagonists for atopic dermatitis: a new era of therapy. Expert opinion on investigational drugs 33 (6) (2024)
Saam Foroshani, Avrohom Karp, Wilbert S Aronow, Gregg M Lanier
The role of phosphodiesterase 9A inhibitors in heart failure. Expert opinion on investigational drugs 33 (6) (2024)
Prithvi Reddy Akepati, Eric M Gochanour
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis. Expert opinion on investigational drugs 33 (6) (2024)
Jiaming Gao, Jingwen Cheng, Wanyu Xie, Ping Zhang, Xuebin Liu, Zaiqi Wang, Baoyuan Zhang
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study. Expert opinion on investigational drugs 33 (6) (2024)
Fernanda Karoline Vieira da Silva Torchelsen, Ana Lia Mazzeti, Vanessa Carla Furtado Mosqueira
Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status. Expert opinion on investigational drugs 33 (6) (2024)
Nadia Saoudi González, Paola Valeria Marchese, Iosune Baraibar, Javier Ros, Francesc Salvà, Marta Rodríguez, Clara Salvà, Caterina Vaghi, Adriana Alcaraz, Ariadna García, Josep Tabernero, Elena Élez
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy. Expert opinion on investigational drugs 33 (6) (2024)

volume 33, number 7, 2024

P Mihika S Fernando, Amanda J Hooper, John R Burnett
Lepodisiran, an siRNA targeting lipoprotein(a) for the potential future treatment of cardiovascular disease. Expert opinion on investigational drugs 33 (7) (2024)
Ling Yang, Yuan Fang, Yuan Luo, Meng Fu, Kai Shen, Zhu Luo
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study. Expert opinion on investigational drugs 33 (7) (2024)
Luca Iorio, Roberto Padoan, Milena Bond, Christian Dejaco
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development. Expert opinion on investigational drugs 33 (7) (2024)
Ling Yang, Yuan Fang, Yuan Luo, Meng Fu, Kai Shen, Zhu Luo
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study. Expert opinion on investigational drugs 33 (7) (2024)
Shogo Hashimoto, Narihito Nagoshi, Masaya Nakamura, Hideyuki Okano
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration. Expert opinion on investigational drugs 33 (7) (2024)
Amedeo De Grado, Chiara Pisciotta, Paola Saveri, Davide Pareyson
Will new investigational drugs change the way we treat Charcot-Marie-Tooth disease? Expert opinion on investigational drugs 33 (7) (2024)
Shogo Hashimoto, Narihito Nagoshi, Masaya Nakamura, Hideyuki Okano
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration. Expert opinion on investigational drugs 33 (7) (2024)
Ava Aghakhani, Parmida Sadat Pezeshki, Nima Rezaei
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy. Expert opinion on investigational drugs 33 (7) (2024)
Virginia Fuochi, Salvatore Furnari, Laura Trovato, Maddalena Calvo, Pio Maria Furneri
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies. Expert opinion on investigational drugs 33 (7) (2024)
Aliki I Venetsanopoulou, Paraskevi V Voulgari, Alexandros A Drosos
Investigational bispecific antibodies for the treatment of rheumatoid arthritis. Expert opinion on investigational drugs 33 (7) (2024)
Nadia Martinez Naya, Jazmin Kelly, Austin Hogwood, Antonio Abbate, Stefano Toldo
Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases. Expert opinion on investigational drugs 33 (7) (2024)

volume 33, number 8, 2024

Na Hyun Kim, Mehdi Hamadani, Sameem Abedin
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature. Expert opinion on investigational drugs 33 (8) (2024)
Claudio Cruciani, Mariele Gatto, Luca Iaccarino, Andrea Doria, Margherita Zen
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development. Expert opinion on investigational drugs 33 (8) (2024)
Amanda J Hooper, Xuan L Tang, John R Burnett
VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol. Expert opinion on investigational drugs 33 (8) (2024)
Jian Liu, Qingwei Zhao, You Zhai, Xia Wu, Jiejing Kai, Jie Ruan, Minglan Wu, Meijia Wu, Zhuojun Zhou, Yuemei Yan, Jinzi J Wu, Yunqing Qiu
Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects. Expert opinion on investigational drugs 33 (8) (2024)
Edoardo Crimini, Curigliano Giuseppe
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate. Expert opinion on investigational drugs 33 (8) (2024)
Marco Sebastiani, Andreina Manfredi, Stefania Croci, Paola Faverio, Giulia Cassone, Caterina Vacchi, Carlo Salvarani, Fabrizio Luppi
Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs. Expert opinion on investigational drugs 33 (8) (2024)
Elisabeth Amadeo, Silvia Foti, Silvia Camera, Federico Rossari, Mara Persano, Federica Lo Prinzi, Francesco Vitiello, Andrea Casadei-Gardini, Margherita Rimini
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents. Expert opinion on investigational drugs 33 (8) (2024)
Na Hyun Kim, Mehdi Hamadani, Sameem Abedin
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature. Expert opinion on investigational drugs 33 (8) (2024)
William C Upshaw, John M Richey, Gurjot Ravi, Adrian Chen, Shahab Ahmadzadeh, Sahar Shekoohi, Omar Viswanath, Alan D Kaye
An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions. Expert opinion on investigational drugs 33 (8) (2024)
Lorenza Magagnoli, Paola Ciceri, Mario Gennaro Cozzolino
Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs. Expert opinion on investigational drugs 33 (8) (2024)
Na Hyun Kim, Mehdi Hamadani, Sameem Abedin
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature. Expert opinion on investigational drugs 33 (8) (2024)
Jian Liu, Qingwei Zhao, You Zhai, Xia Wu, Jiejing Kai, Jie Ruan, Minglan Wu, Meijia Wu, Zhuojun Zhou, Yuemei Yan, Jinzi J Wu, Yunqing Qiu
Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects. Expert opinion on investigational drugs 33 (8) (2024)
Robert H Gaffey, Afua K Takyi, Alpana Shukla
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity. Expert opinion on investigational drugs 33 (8) (2024)